News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Government Ayurveda College & Hospital will include an infrastructure for the College and a 100 bedded hospital, hostel block for students and staff quarters.
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
